Brief: Actinium begins new Actimab-A trial combining Venetoclax and ASTX-727 to treat patients newly diagnosed with AML in partnership with NCI
11/03/2025 14:39
March 11 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A: ACTINIUM PHARMACEUTICALS ANNOUNCES INITIATION OF ACTIMAB-A TRIPLET COMBINATION FRONTLINE TRIAL UNDER NCI CRADA WITH VENETOCLAX AND TAIHO ONCOLOGY'S HYPOMETHYLATING AGENT ASTX-727 IN PATIENTS WITH NEWLY DIAGNOSED AML Source text: nPn2CDTHVa Further company coverage: ATNM.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities